CN102614248B - Traditional Chinese herbal composite for treating stroke and chest obstruction - Google Patents
Traditional Chinese herbal composite for treating stroke and chest obstruction Download PDFInfo
- Publication number
- CN102614248B CN102614248B CN 201210108324 CN201210108324A CN102614248B CN 102614248 B CN102614248 B CN 102614248B CN 201210108324 CN201210108324 CN 201210108324 CN 201210108324 A CN201210108324 A CN 201210108324A CN 102614248 B CN102614248 B CN 102614248B
- Authority
- CN
- China
- Prior art keywords
- water
- time
- extracted
- hours
- add
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Landscapes
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention discloses a traditional Chinese herbal composite for treating stroke and chest obstruction, which is characterized in that: 400-600g of milkvetch root, 200-400g of rhodiola rosea and 100-300g of safflower are taken, water is added to extract for three times, 10 times of water is added for the first time to extract for 3 hours, 8 times of water is added for the second time to extract for 2 hours, 8 times of water is added for the third time to extract for 1 hour, extract powder is obtained after concentration and drying, pharmaceutically acceptable auxiliary materials are added to produce capsules, tablets, granules and other solid oral dosage forms which are used for treating stroke and chest obstruction, and a good effect is obtained.
Description
Technical field
The present invention relates to the field of Chinese medicines, be specifically related to a kind of Chinese medicine composition for the treatment of apoplexy and the thoracic obstruction.
Background technology
Apoplexy has another name called apoplexy, mainly show as to fall forward unexpected dusk, hemiplegia, crooked mouth and tongue, stuttering puckery, the hemianesthesia of speech, and have onset anxious, change characteristics fast, that become as ailment said due to cold or exposure benefaction number.Thoracic obstruction doctor trained in Western medicine is called coronary heart disease, mainly shows as feeling of oppression and pain in the chest, shortness of breath and palpitation, dizzy weak.Along with the raising of people's living standard, apoplexy and thoracic obstruction sickness rate are high, have a strong impact on people's quality of life.I use Radix Hedysari, Radix Rhodiolae, Flos Carthami prescription therapeutic apoplexy, the thoracic obstruction for many years, obtain good result, for vast apoplexy, thoracic obstruction patient provide a kind of good medicine safely and effectively.
Summary of the invention
The present invention is foundation tcm clinical practice experience for many years, in conjunction with the modern Chinese medicine preparation technique, provides a kind of Chinese medicine composition for the treatment of apoplexy and the thoracic obstruction.
Invention embodiment is as follows:
Get Radix Hedysari 400～600g, Radix Rhodiolae 200～400g, Flos Carthami 100～300g, extracting in water three times adds 10 times of water gagings for the first time, extracts 3 hours, for the second time add 8 times of water gagings, extracted 2 hours, add 8 times of amounts of water for the third time, extracted 1 hour, concentrate, drying gets the extraction powder, add the pharmacy acceptable auxiliary, make solid oral dosage forms such as capsule, tablet, granule.
The raw material standards that above-mentioned embodiment is mentioned is as follows:
Radix Hedysari: Chinese Pharmacopoeia version one ministerial standard in 2010, be the dry root of leguminous plant Hedysarum polybotrys Hand.-Mazz. Hedysarum polybotrys Hand Mazz, two seasons of spring and autumn excavate, and remove fibrous root, dry.
Radix Rhodiolae: Chinese Pharmacopoeia version one ministerial standard in 2010, be dry root and the rhizome of Crassulaceae plant Radix Rhodiolae Rhodiola crenulata H.Ohba, excavate autumn, removes rough bark, cleans, and dries.
Flos Carthami: Chinese Pharmacopoeia version one ministerial standard in 2010, be the dried floral of feverfew Flos Carthami Carthamus tinctorius L, pluck summer, dries.
Above Chinese crude drug all can be bought from pharmaceuticals and obtain, and all can be used to implement the present invention program as long as satisfy national standard.
The specific embodiment
Specific embodiments of the invention 1
Get Radix Hedysari 500g, Radix Rhodiolae 300g, Flos Carthami 200g, extracting in water three times, for the first time add 10 times of water gagings, extracted 3 hours, add 8 times of water gagings the second time, extracts 2 little, add 8 times of amounts of water for the third time, extracted 1 hour, get extracting solution, spray drying, must extract powder, add starch 100g, with 40% ethanol wet granulation, 60 ℃ of dryings, granulate adds the 1g magnesium stearate, mixing is pressed into 1000, gets a day stilbene sheet.
Specific embodiments of the invention 2
Get Radix Hedysari 400g, Radix Rhodiolae 200g, Flos Carthami 100g, extracting in water three times, for the first time add 10 times of water gagings, extracted 3 hours, add 8 times of water gagings the second time, extracts 2 little, add 8 times of amounts of water for the third time, extracted 1 hour, get extracting solution, vacuum concentration, 60 ℃ of drying under reduced pressure are pulverized, must extract powder, add starch 100g, Pulvis Talci 5g mixing, incapsulate, make 1000, get a day astragalus capsules.
Specific embodiments of the invention 3
Get Radix Hedysari 600g, Radix Rhodiolae 400g, Flos Carthami 300g, extracting in water three times, for the first time add 10 times of water gagings, extracted 3 hours, add 8 times of water gagings the second time, extracts 2 little, add 8 times of amounts of water for the third time, extracted 1 hour, get extracting solution, spray drying, must extract powder, add lactose 300g, dextrin 100g, the water wet granulation, 60 ℃ of dryings, granulate, add Pulvis Talci 5g, mixing gets a day stilbene granule.
Specific embodiments of the invention 4
Get Radix Hedysari 500g, Radix Rhodiolae 300g, Flos Carthami 200g, extracting in water three times, for the first time add 10 times of water gagings, extracted 3 hours, add 8 times of water gagings the second time, extracts 2 little, add 8 times of amounts of water for the third time, extracted 1 hour, get extracting solution, spray drying, must extract powder, add 200g polyethylene glycol 6000 mixing, 80 ℃ of control temperature of charge, 4 ℃ of condensation temperatures are dripped 30～20 of fast per minutes, splash in the liquid paraffin, drop pill takes out after being shaped, and inhales and removes surface cool liquid, is drying to obtain a day root-astragalus root dripping pill.
Specific embodiments of the invention 5
Get Radix Hedysari 500g, Radix Rhodiolae 300g, Flos Carthami 200g, extracting in water three times adds 10 times of water gagings for the first time, extracts 3 hours, for the second time add 8 times of water gagings, extract 2 for a short time, add 8 times of amounts of water for the third time, extracted 1 hour, and got extracting solution, spray drying, powder be must extract, 1g sodium benzoate and 2000g purified water added, high pressure steam sterilization, be distributed into 200 bottles, namely get a day stilbene oral liquid.
Above result shows that embodiment of the present invention all can be made into Chinese patent medicine, list marketing.The sky astragalus capsules that makes with embodiment 2 illustrates implementation result of the present invention below:
The content assaying method of 2 days astragalus capsules of test example one specific embodiment
Measure according to high performance liquid chromatography (an appendix VI of Chinese Pharmacopoeia version in 2010 D).
Chromatographic condition and system suitability test are filler with octadecylsilane chemically bonded silica; Acetonitrile-water (7: 93) is mobile phase; The detection wavelength is 225nm.Number of theoretical plate calculates by the rhodioside peak should be not less than 2500.
The preparation precision of reference substance solution takes by weighing rhodioside reference substance 6.6mg, puts in the 50ml measuring bottle, adds methanol to scale, shakes up, namely.
This product content is got in the preparation of need testing solution, porphyrize, and precision takes by weighing about 1.0g, and to the 100ml measuring bottle, the accurate methanol 100ml that adds weighs.Ultrasonic 3 times, each 15 minutes.Weigh again, supply the methanol weight that subtracts mistake, namely.
Accurate reference substance and each the 6 μ l injection chromatograph of liquid of need testing solution drawn of algoscopy measured, namely.
Every of this product contains rhodioside must not be less than 2.0mg.
2 days astragalus capsules of test example two specific embodiments are to the influence of rat platelet aggregation function
1 test material
Reagent: thing of the present invention (by the sky astragalus capsules of embodiment 2 preparations);
Contrast medicine: stilbene trematodiasis capsule (sky, Heilungkiang dagger-axe Pharmaceutical Co., Ltd);
Blank: normal saline (Tri-Lion Pharmaceutical Co., Ltd., Harbin);
Animal: wistar rat (pharmaceutical college of Jiamusi University pharmacological testing center);
2 test methods
Get 30 of rats, body weight 150～160g, be divided into 3 groups at random, test group is taken thing of the present invention sky astragalus capsules, and matched group is taken stilbene trematodiasis capsule, blank group is taken normal saline, gastric infusion, every day 1 time, continuous 5 days, get blood 2ml from eye socket, be collected in the plastic centrifuge tube, per minute 1000 left the heart 10 minutes under room temperature, separated the PRP(platelet rich plasma), per minute 3000 left the heart 20 minutes, separate the PPP(platelet poor plasma), assembled every milliliter of 10 μ g of ADP final concentration by the ADP induced platelet, record maximum agglutination rate, obtain the half-inhibition concentration IC50 of medicine with return law of the straight line.
3 result of the tests
Table 1 day astragalus capsules is to the influence of rat platelet aggregation function
4 conclusion (of pressure testing)s
Above-mentioned result of the test shows that the sky astragalus capsules of the present invention's preparation is significantly higher than stilbene trematodiasis capsule, p＜0.01 to the rat platelet suppression ratio.
2 days astragalus capsules of test example three specific embodiments are to the influence of rat to clotting time of mice
1 test material
Reagent: thing of the present invention (by the sky astragalus capsules of embodiment 2 preparations);
Contrast medicine: stilbene trematodiasis capsule (sky, Heilungkiang dagger-axe Pharmaceutical Co., Ltd);
Blank: normal saline (Tri-Lion Pharmaceutical Co., Ltd., Harbin);
Animal: Kunming mouse (pharmaceutical college of Jiamusi University pharmacological testing center);
2 test methods
Get 30 of mices, body weight 18～24g is divided into 3 groups at random, the difference gastric infusion, and every day 1 time, continuous 7 days, 1 hour capillary tube method was measured clotting time of mice after the last administration.
3 result of the tests
Table 2 day astragalus capsules is to the influence of clotting time of mice
4 conclusion (of pressure testing)s
Above-mentioned result of the test shows, the sky astragalus capsules of the present invention's preparation can the external clotting time of significant prolongation mice, p＜0.05.
Test example four specific embodiments astragalus capsules treatment in 2 days apoplexy clinical observation on the therapeutic effect
1 case situation
Observe apoplexy case 240 examples altogether, male 98 examples, women 142 examples, the age is 38～76 years old, 55 years old mean age.The patient has in various degree hemiplegia, has a dizzy spell, susceptible to lose temper due to restlessness, feels the symptom that goes down, and is diagnosed as apoplexy by the diagnostic criteria of new Chinese medicine treatment apoplexy clinical research guideline tcm syndrome.The patient is divided into two groups at random, and test group is taken a day astragalus capsules, and matched group is taken commercially available BUCHANG NAOXINTONG JIAONANG.
2 efficacy assessment standards
Treat apoplexy clinical research guideline tcm syndrome curative effect determinate standard according to new Chinese medicine:
Cure: tcm clinical practice symptom, sign disappear or basic the disappearance, and the syndrome integration reduces 〉=95%.
Produce effects: tcm clinical practice symptom, sign are obviously improved, and the syndrome integration reduces 〉=70%.
Effectively: tcm clinical practice symptom, sign all take a favorable turn, and the syndrome integration reduces 〉=30%.
Invalid: tcm clinical practice symptom, sign all do not have and obviously improve or increase the weight of, and the syndrome integration reduces＜30%.
Computing formula: [integration before (integration before the treatment-treatment back integration) ÷ treatment] * 100%.
3 clinical observation result
Table 1 day astragalus capsules and BUCHANG NAOXINTONG clinical efficacy contrast table
Above-mentioned clinical observation on the therapeutic effect result shows, during the sky astragalus capsules treatment apoplexy of the present invention's preparation, and the BUCHANG NAOXINTONG that is higher than evident in efficacy, p＜0.05.
Test example five specific embodiments astragalus capsules treatment in 2 days thoracic obstruction clinical observation on the therapeutic effect
1 case situation
Observe thoracic obstruction case 168 examples altogether, male 88 examples, women 80 examples, the age is 32～68 years old, 46 years old mean age.The patient have in various degree uncomfortable in chest, pained, breathe hard, cardiopalmus, dizzy symptom, be diagnosed as the thoracic obstruction by the diagnostic criteria of new Chinese medicine treatment coronary heart disease clinical research guideline tcm syndrome.The patient is divided into two groups at random, and test group is taken a day astragalus capsules, and matched group is taken commercially available Jingzhi Guanxin tablet.
2 efficacy assessment standards
Treat coronary heart disease clinical research guideline tcm syndrome curative effect determinate standard according to new Chinese medicine:
Produce effects: tcm clinical practice symptom, sign are obviously improved, and the syndrome integration reduces 〉=70%.
Effectively: tcm clinical practice symptom, sign all take a favorable turn, and the syndrome integration reduces 〉=30%.
Invalid: tcm clinical practice symptom, sign all do not have and obviously improve or increase the weight of, and the syndrome integration reduces＜30%.
Increase the weight of: tcm clinical practice symptom, sign all have and increase the weight of, and the syndrome integration reduces＜0.
Computing formula: [integration before (integration before the treatment-treatment back integration) ÷ treatment] * 100%.
3 clinical observation result
Table 2 day astragalus capsules and Jingzhi Guanxin tablet clinical efficacy contrast table
Above-mentioned clinical observation on the therapeutic effect result shows, during the sky astragalus capsules treatment thoracic obstruction of the present invention's preparation, and the Jingzhi Guanxin tablet that is higher than evident in efficacy, p＜0.05.
Claims (5)
1. a Chinese medicine composition for the treatment of apoplexy and the thoracic obstruction is characterized in that getting Radix Hedysari 400～600g, Radix Rhodiolae 200～400g, Flos Carthami 100～300g, extracting in water three times adds 10 times of water gagings for the first time, extracted 3 hours, and added 8 times of water gagings for the second time, extracted 2 hours, add 8 times of amounts of water for the third time, extracted 1 hour, concentrate, dry, must extract powder, add the pharmacy acceptable auxiliary, make solid oral dosage form.
2. according to the described Chinese medicine composition of claim 1, it is characterized in that getting Radix Hedysari 500g, Radix Rhodiolae 300g, Flos Carthami 200g, extracting in water three times adds 10 times of water gagings for the first time, extracts 3 hours, adds 8 times of water gagings for the second time, extracted 2 hours, and added 8 times of amounts of water for the third time, extracted 1 hour, get extracting solution, spray drying gets the extraction powder, adds starch 100g, with 40% ethanol wet granulation, 60 ℃ of dryings, granulate, add the 1g magnesium stearate, mixing is pressed into 1000 tablets of tablets.
3. according to the described Chinese medicine composition of claim 1, it is characterized in that getting Radix Hedysari 400g, Radix Rhodiolae 200g, Flos Carthami 100g, extracting in water three times adds 10 times of water gagings for the first time, extracts 3 hours, adds 8 times of water gagings for the second time, extracted 2 hours, and added 8 times of amounts of water for the third time, extracted 1 hour, get extracting solution, vacuum concentration, 60 ℃ of drying under reduced pressure, pulverize, get the extraction powder, add starch 100g, Pulvis Talci 5g mixing incapsulates, and makes 1000 seed lac wafers.
4. according to the described Chinese medicine composition of claim 1, it is characterized in that getting Radix Hedysari 600g, Radix Rhodiolae 400g, Flos Carthami 300g, extracting in water three times adds 10 times of water gagings for the first time, extracts 3 hours, adds 8 times of water gagings for the second time, extracted 2 hours, and added 8 times of amounts of water for the third time, extracted 1 hour, get extracting solution, spray drying gets the extraction powder, adds lactose 300g, dextrin 100g, the water wet granulation, 60 ℃ of dryings, granulate, add Pulvis Talci 5g, mixing is made the 1000g granule.
5. according to the described Chinese medicine composition of claim 1, it is characterized in that getting Radix Hedysari 500g, Radix Rhodiolae 300g, Flos Carthami 200g, extracting in water three times adds 10 times of water gagings for the first time, extracted 3 hours, for the second time add 8 times of water gagings, extracted 2 hours, add 8 times of amounts of water for the third time, extracted 1 hour, get extracting solution, spray drying gets the extraction powder, add 200g polyethylene glycol 6000 mixing, 80 ℃ of control temperature of charge, 4 ℃ of condensation temperatures are dripped 30～20 of fast per minutes, splash in the liquid paraffin, drop pill takes out after being shaped, and inhales and removes surface cool liquid, is drying to obtain drop pill.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 201210108324 CN102614248B (en) | 2012-04-13 | 2012-04-13 | Traditional Chinese herbal composite for treating stroke and chest obstruction |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 201210108324 CN102614248B (en) | 2012-04-13 | 2012-04-13 | Traditional Chinese herbal composite for treating stroke and chest obstruction |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN102614248A CN102614248A (en) | 2012-08-01 |
| CN102614248B true CN102614248B (en) | 2013-08-07 |
Family
ID=46554697
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 201210108324 Active CN102614248B (en) | 2012-04-13 | 2012-04-13 | Traditional Chinese herbal composite for treating stroke and chest obstruction |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102614248B (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106166198A (en) * | 2016-10-02 | 2016-11-30 | 成都市飞龙水处理技术研究所 | A kind of for treating apoplexy capsule medicine with the thoracic obstruction and preparation method thereof |
| CN107050108A (en) * | 2017-06-20 | 2017-08-18 | 佳木斯诺亚医药科技有限公司 | Daybreak pellet drop pills and preparation method thereof |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1977890A (en) * | 2005-11-29 | 2007-06-13 | 江苏中康药物科技有限公司 | Chinese medicine composition and its use |
-
2012
- 2012-04-13 CN CN 201210108324 patent/CN102614248B/en active Active
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1977890A (en) * | 2005-11-29 | 2007-06-13 | 江苏中康药物科技有限公司 | Chinese medicine composition and its use |
Non-Patent Citations (2)
| Title |
|---|
| 中药治疗心血管病研究现状;罗万玲等;《云南中医中药杂志》;20061020;第27卷(第05期);50-52 * |
| 罗万玲等.中药治疗心血管病研究现状.《云南中医中药杂志》.2006,第27卷(第05期), |
Also Published As
| Publication number | Publication date |
|---|---|
| CN102614248A (en) | 2012-08-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN110787233B (en) | Liver-protecting traditional Chinese medicine composition, extract and pharmaceutical application thereof | |
| CN101919913B (en) | Composition with effect of treating rheumatoid arthritis | |
| CN101991785B (en) | Lonicerae and Forsythiae detoxication soft capsule medicine and preparation method and quality detection method thereof | |
| CN101502579A (en) | Chinese medicinal composition for treating digestive tumor and preparation method thereof | |
| CN102579518B (en) | Pterocephalus hookeri (C.B.Clarke) Hoeck total saponin extract and preparation method and application thereof | |
| CN102258742B (en) | Chinese medicinal medicine composition for treating depression and preparation method thereof | |
| CN101926815B (en) | Paeoniflorin and glycyrrhetinic acid composition and preparation method and application thereof | |
| CN104173950B (en) | A kind of herbal composite for treating prostate cancer | |
| CN103735712B (en) | Preparation method of Chinese medicinal composition and Chinese medicinal composition prepared by using preparation method | |
| CN102614248B (en) | Traditional Chinese herbal composite for treating stroke and chest obstruction | |
| CN1923263B (en) | Traditional Chinese medicine composition, its preparing method and quality controlling means | |
| CN111375035B (en) | Preparation and application of enteric-coated preparation for treating cervical spondylosis | |
| CN1961898B (en) | An antitumor compound pharmaceutical composition with barbed stullcap and preparation process thereof | |
| CN101569682B (en) | Medical composition for treating rheumatoid arthritis and preparation method | |
| CN104042895A (en) | Traditional Chinese medicine composition for treating systemic lupus erythematosus and use thereof | |
| CN103520367B (en) | A kind of pharmaceutical composition for the treatment of urticaria and its production and use | |
| CN102362993B (en) | Chinese medicinal preparation with effects of protecting intestines and removing toxic materials, and preparation method thereof | |
| CN108452008A (en) | A kind of application including Common Leafflower Herb, rainbow conk, Radix Salviae Miltiorrhizae and the Chinese medicine composition of Asian puccoon in preparing the drug for inhibiting recurrence of PHC | |
| CN103705812B (en) | A kind of pharmaceutical composition for the treatment of gout and its production and use | |
| CN102652774A (en) | Drug composition for treating leukopenia and hypoimmunity caused by chemoradiotherapy and preparation method and quality detection method | |
| CN102349956B (en) | Compound extract for moisturizeing pathogenic dryness and relieving itching and preparation thereof | |
| CN102813873A (en) | Traditional Chinese medicine composition for treating mental diseases, and preparation method, application and quality control thereof | |
| CN1927309B (en) | Traditional Chinese medicine composition detection method | |
| CN100333771C (en) | Ginseng and astragalis blood glucose loucring dorpping pill, and its preparing and detecting method | |
| CN102284036A (en) | Gujinwan capsule and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| ASS | Succession or assignment of patent right |
Owner name: HEILONGJIANG TIANYI PHARMACEUTICAL CO., LTD. Free format text: FORMER OWNER: SUN CHANGHAI Effective date: 20140604 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 154007 JIAMUSI, HEILONGJIANG PROVINCE TO: 163316 DAQING, HEILONGJIANG PROVINCE |
|
| TR01 | Transfer of patent right |
Effective date of registration: 20140604 Address after: 163316 Daqing high tech Zone, Heilongjiang, Jianshe Road, No. 245, No. Patentee after: Heilongjiang Tianyi Pharmaceutical Co., Ltd. Address before: 154007 D school pharmacy, 148 School Road, Jiamusi,, Heilongjiang Patentee before: Sun Changhai |
|
| ASS | Succession or assignment of patent right |
Owner name: ZHAO YANYI Free format text: FORMER OWNER: HEILONGJIANG TIANYI PHARMACEUTICAL CO., LTD. Effective date: 20141102 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 163316 DAQING, HEILONGJIANG PROVINCE TO: 163311 DAQING, HEILONGJIANG PROVINCE |
|
| TR01 | Transfer of patent right |
Effective date of registration: 20141102 Address after: Saertu District of Heilongjiang city in Daqing province by the 163311 Street 0-12 No. 3 Room 502 Patentee after: Zhao Yanyi Address before: 163316 Daqing high tech Zone, Heilongjiang, Jianshe Road, No. 245, No. Patentee before: Heilongjiang Tianyi Pharmaceutical Co., Ltd. |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20170106 Address after: 163316 Jianshe Road high tech Zone, Heilongjiang, No. 245, Patentee after: Heilongjiang Tianyi Pharmaceutical Co., Ltd. Address before: Saertu District of Heilongjiang city in Daqing province by the 163311 Street 0-12 No. 3 Room 502 Patentee before: Zhao Yanyi |